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The insulin-like growth factor II/mannose-6-
phosphate receptor (IGF2R) mediates traffick-
ing of mannose-6-phosphate (M6P)-containing
proteins and the mitogenic hormone IGF2.
IGF2R also plays an important role as a tumor
suppressor, as mutation is frequently associ-
ated with human carcinogenesis. IGF2 binds
to domain 11, one of 15 extracellular domains
on IGF2R. The crystal structure of domain 11
and the solution structure of IGF2 have been re-
ported, but, to date, there has been limited suc-
cess when using crystallography to study the
interaction of IGFs with their binding partners.
As an approach to investigate the interac-
tion between IGF2 and IGF2R, we have used
heteronuclear NMR in combination with exist-
ing mutagenesis data to derive models of the
domain 11-IGF2 complex by using the program
HADDOCK. The models reveal that the molecu-
lar interaction is driven by critical hydrophobic
residues on IGF2 and IGF2R, while a ring of flex-
ible, charged residues on IGF2R may modulate
binding.
INTRODUCTION
The insulin-like growth factor II/mannose-6-phosphate re-
ceptor (IGF2R) is a multifunctional cell-surface glycopro-
tein receptor expressed ubiquitously in human tissue
(Braulke, 1999). The receptor is continually cycled be-
tween the cell surface and the trans-Golgi network via cla-
thrin-coated vesicles (Dell’Angelica and Payne, 2001),
mediating the trafficking of mannose-6-phosphate
(M6P)-containing lysosomal enzymes from the trans-Golgi
network to the lysosomes. Additionally, IGF2R functions in
the capture and activation/degradation of extracellular
M6P-bearing ligands and in cycling of the nonglycosly-Structure 15, 1065–107ated polypeptide insulin-like growth factor II (IGF2)
(Dahms et al., 1989; Ellis et al., 1996).
IGF2R is composed of a short C-terminal cytoplasmic
domain connected via a single transmembrane domain
to an extracellular region consisting of 15 homologous re-
peats (16%–38% identity) (Dahms and Hancock, 2002)
(Figure 1A). Elucidation of the crystal structures of do-
mains 1, 2, 3 (Olson et al., 2004), and 11 (Brown et al.,
2002) indicates that each domain shares a similar topol-
ogy, consisting of a flattened b barrel composed of two
four-stranded antiparallel b sheets held together by four
conserved disulphide bonds. Domains 3, 5, and 9 have
been shown to bind M6P-containing ligands (Dahms,
1996; Reddy et al., 2004), while IGF2 binding has been lo-
calized to domain 11 (Garmroudi et al., 1996); domain 13 is
proposed to enhance binding by reducing the rate of IGF2
release (Devi et al., 1998; Linnell et al., 2001). Traditionally
assumed to be a monomer, recent work suggests that
IGF2R functions as a homodimer in the membrane for
high-affinity M6P binding and efficient internalization of li-
gands (Byrd et al., 2000). Such dimerization events may
act to stabilize important functional features of the recep-
tor, such as cooperation in IGF2 binding between repeats
11 and 13.
IGF2 is a small, acidic polypeptide with a high degree of
sequence identity and structural homology to IGF1 and in-
sulin (Torres et al., 1995). IGF2 has a wide range of biolog-
ical activities, playing key roles in mammalian growth and
development, cell division, and differentiation, as well as
having insulin-like activity (Lelbach et al., 2005). The bio-
logical actions of IGF2 are mediated through the type 1
IGF receptor (IGF1R), a tyrosine kinase that resembles
the insulin receptor in structure (Ullrich et al., 1986). In
mammals, IGF2 activity is tightly regulated by six high-
affinity IGF-binding proteins (IGFBPs 1–6), while IGF2R
at the cell surface is involved in clearing free IGF2 from
the circulation by targeting it for lysosomal degradation
(Dahms et al., 1989; Ellis et al., 1996).
Transcription of both IGF2 and IGF2R is subject to ge-
nomic imprinting, an epigenetic form of gene regulation
that leads to mRNA production from only one allele (Killian
et al., 2000) depending on the sex of the parent from8, September 2007 ª2007 Elsevier Ltd All rights reserved 1065
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Interaction of IGF2 with IGF2R Domain 11Figure 1. IGF2 Binding Pocket of IGF2R Domain 11 and Its Evolution
(A) Proposed model of IGF2R showing the IGF2 binding site located in domain 11. Domain 13, orientated on the same side of the receptor, is impli-
cated in enhancing IGF2 binding affinity through a type II fibronectin insert.
(B) Domain 11 sequence alignment of the loop regions from vertebrates. Sequences were aligned by using ClustalW. Changes in the proposed IGF2
binding site are marked in green for marsupials, pink for monotremes, and orange for birds/fish.
(C) Binding epitopes of domain 11. Residues that constitute the principal hydrophobic binding site are shown in green and are surrounded by
a charged second sphere of residues in red.whom the allele was inherited. Aberrant regulation of IGF2
through loss of imprinting has been linked to various car-
cinomas (Cruz-Correa et al., 2004; Ulaner et al., 2003;
Kohda et al., 2001) and solid tumors (Ravenel et al.,
2001). IGF2R is silent on the paternal chromosome, and
a loss of heterozygosity and somatic mutations of IGF2R
have been detected in tumor types including breast, liver,
and lung (Hebert, 2006). Conversely, overexpression of
IGF2R has been shown to cause an IGF2-dependent de-
crease in growth and to increase apoptosis in tumor
models (Harper et al., 2006), and, as such, IGF2R is often
referred to as a tumor suppressor.
IGF2/IGF2R imprinting is also species dependent. Both
IGF2 and IGF2R are imprinted in viviparous mammals, but
not in monotremes or birds (Killian et al., 2001). As the im-
printing of the IGF2/IGF2R genes has evolved over the last
150 million years as animals evolved from lizard-like an-
cestors to placental mammals, the resulting evolutionary
pressure has lead to an increase in the affinity of IGF2R
for IGF2 (John and Surani, 2000). For example, IGF2R
from placental mammals displays high-affinity binding
for IGF2, while binding in marsupials is relatively weak
(Yandell et al., 1999). In contrast, the egg-laying mono-
treme IGF2R, like amphibian and chicken IGF2Rs, cannot
bind IGF2 (Killian et al., 2000). Analysis of the domain 111066 Structure 15, 1065–1078, September 2007 ª2007 Elseviersequences from a variety of species has led to speculation
regarding residues that may be important for IGF2 bind-
ing, but the functional importance of these residues can-
not be discerned from the domain 11 structure alone.
The crystal structure of domain 11 has revealed the
presence of a shallow hydrophobic pocket on the protein
surface (Brown et al., 2002), spatially analogous to the
hydrophilic sugar-binding sites of domains 3 and 9 (Olson
et al., 2004). A detailed analysis of this region by alanine
mutagenesis revealed that hydrophobic residues on the
CD loop and, to a lesser extent, the FG loop form the
hydrophobic core of the IGF2 binding pocket (Figure 1B)
(Linnell et al., 2001; Zaccheo et al., 2006). In particular,
F1567 and I1572 in the CD loop are critical for IGF2 bind-
ing, and mutation of either residue to alanine completely
abolishes IGF2 binding. This work also led to the unusual
discovery of an amino acid residue in the binding site that
has evolved to negatively regulate IGF2 binding affinity.
Mutating E1544 in the human receptor to a lysine in-
creases binding 6-fold (KD of 14 nM). It has been proposed
that E1544 may form part of an outer ‘‘O’’-ring or second
sphere comprised of charged, partially hydrated side
chains that may positively or negatively modulate binding
affinity via stabilizing hydrogen bonds and salt bridges
(Figure 1C).Ltd All rights reserved
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Interaction of IGF2 with IGF2R Domain 11The 3D structures of IGF2 (Torres et al., 1995) and
IGF2R domains (Olson et al., 2004; Brown et al., 2002)
have been determined, but there is relatively little informa-
tion regarding the orientation of the ligand in the IGF2-
IGF2R complex. Mutagenesis studies on IGF2 have iden-
tified several residues that are important for the interaction
with IGF2R (F48, R49, S50, A54, and L55) (Sakano et al.,
1991; Burgisser et al., 1991). Recently, however, T16,
F19, D52, and L53 have been shown to be critical for
IGF2R binding (Delaine et al., 2007), and A54 and L55
have been shown to have less influence than previously
reported (Forbes et al., 2001). IGFs are difficult molecules
to study structurally, as they typically contain regions of
high mobility, undergo nonuniform and complicated back-
bone dynamics, and aggregate in solution at millimolar
concentrations. Therefore, to date, there has been limited
success when using crystallography to study the interac-
tion of IGFs with their binding partners. In the work pre-
sented here, we have used heteronuclear NMR to study
the interaction of IGF2R domain 11, herein referred to as
domain 11, with IGF2 in solution. A model of the domain
11-IGF2 complex was then generated by using NMR
and mutagenesis data to drive the docking of the complex
with the program HADDOCK (Dominguez et al., 2003).
Combined with recent mutagenesis data, the structural
model aims to provide a detailed understanding of the
physical basis for the recognition and interaction of IGF2
by domain 11.
RESULTS AND DISCUSSION
Expression and Purification of IGF2
with a NusA Fusion Partner
The production of recombinant IGF2 in Escherichia coli is
typically hampered by low yields due to poor expression,
insolubility issues, or the need for multiple purification
steps (Sakano et al., 1991; Upton et al., 1995; Wilkinson
et al., 2004). As such, the use of standard constructs
and protocols for heteronuclear NMR studies would be
unsuitable. To find an improved expression system for
NMR studies, several new constructs were designed by
using commonly available fusion proteins shown to im-
prove the expression and solubility of mammalian proteins
in E. coli. In particular, the NusA fusion system has been
shown to be highly efficient at solubilizing a number of pro-
teins (De Marco et al., 2004). Mature IGF2 was therefore
cloned into the pETM-60 vector (EMBL), with the NusA fu-
sion protein located C-terminally behind a stretch of six
histidines and a TEV cleavage site under the control of
a T7 promoter. Due to the design of the expression vec-
tors, the IGF2 product carries four additional amino acids
(GAMA) at the N terminus. The introduction of a hydropho-
bic N-terminal extension can, in fact, facilitate the correct
folding of the IGF analogs compared with normal-length
IGFs (Francis et al., 1992) and may aid the correct folding
of IGF2 in the bacterial cytoplasm. High expression levels
could be achieved after induction with 1 mM IPTG at 25C,
and 95% of the fusion protein was found in the soluble
fraction (Figure 2A). Fusion protein was initially loadedStructure 15, 1065–1078onto a Ni-NTA column, washed with 5 mM imidazole,
and eluted with 500 mM imidazole. IGF2 was cleaved
from NusA by using TEV protease and was further purified
by using gel filtration. Approximately 5 mg/l of >95% pure
IGF2 could be obtained, which is comparable to amounts
seen in previous studies on IGFs. Electrospray-time of
flight mass spectrometry indicated that a single product
of 7802.2 Da (±1.0 Da) had been produced, which agrees
well with the predicted mass of 7800 Da.
Due to the presence of six cysteine residues, IGFs often
misfold to give distinct isoforms. Commonly, two thermo-
dynamically stable isoforms can form during oxidative re-
folding that differ in the arrangement of two disulfide
bonds (Miller et al., 1993). The second stable disulfide iso-
mer has a similar but more compact tertiary structure than
native IGF (Sato et al., 2000). This leads to a change in the
orientation of helix a3, critical for receptor binding, result-
ing in reduced biological activity. A major consideration,
therefore, when expressing recombinant IGFs is to deter-
mine whether a single biologically active isoform has been
purified. To determine if NusA-IGF2 was active, we first
assessed its binding to domain 11 by using a surface plas-
mon resonance (SPR)-based assay (Zaccheo et al., 2006).
NusA-IGF2 was randomly biotinylated by using biotinami-
dohexanoic acid 3-sulfo-N-hydroxysuccinide ester and
was immobilized on a sensor chip by affinity capture to
streptavidin. Commercial biotinylated IGF2 was used as
a control (Figure 2B). Duplicate injections of domain 11 an-
alyte were performed at concentrations of 4096, 2048,
1024, 512, 256, 128, 64, 32, 16, and 8 nM (Figure 2C).
As equilibrium was achieved over the course of each injec-
tion, the dissociation affinity constant (KD) from steady-
state binding was determined by plotting the response
at equilibrium against analyte concentration and fitting to
a 1:1 binding isotherm (Figure 2D). The resulting sensor-
grams show that IGF2 derived from the NusA fusion gives
a response similar to that observed for commercial IGF2,
indicating that the protein is correctly folded (Figure 2C).
The KD of NusA-IGF2 for domain 11 is 65 ± 12 nM, which
compares well with that of commercial IGF2 (106 ± 4 nM).
The observed differences in affinity between the IGFs may
be due to the presence of NusA, which places IGF2 farther
away from the chip surface, reducing steric hindrance. Ini-
tial attempts to fit the sensorgrams to a standard 1:1 Lang-
muir binding model indicated a slight but significant differ-
ence between the fitted model and the observed curves.
Therefore, the sensorgrams were also fitted to a two-state
model, which takes into account conformational changes
in the binding partners and separates the interaction into
two components. KD values calculated by using the two-
state model were in close agreement with those obtained
from steady-state binding and gave 92 ± 6 nM for NusA-
IGF2 and 163 ± 31 nM for commercial IGF2.
After removal of the NusA fusion tag, HPLC analysis of
the purified NusA-derived IGF2 gave a single peak eluting
at 45% acetonitrile (Figure 2E), suggesting that one ma-
jor isoform had been isolated. The bioactivity of cleaved
IGF2 was further characterized by using SPR and
cell-based assays. To assess the ability of NusA-IGF2 to, September 2007 ª2007 Elsevier Ltd All rights reserved 1067
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Interaction of IGF2 with IGF2R Domain 11Figure 2. Purification and Characterization of NusA-Purified IGF2
(A) Purification of IGF2 analyzed by Coomassie-stained SDS-PAGE. M, molecular weight markers; lane 1, NusA-IGF2 after affinity capture and elution;
lane 2, NusA-IGF2 after TEV cleavage; lane 3, IGF2 after gel filtration; lane 4, final preparation after desalting.
(B) Representative sensorgrams depicting duplicate injections of human domain 11 from 4096 nM to 8 nM binding to immobilized commercial IGF2.
Red lines represent the global fitting of the data set to a two-state (conformational change) binding model.
(C) Representative sensorgrams depicting duplicate injections of human domain 11 from 4096 nM to 8 nM binding to immobilized NusA-IGF2. Red
lines represent the global fitting of the data set to a two-state (conformational change) binding model.
(D) Examples of binding isotherms obtained from steady-state analysis of the above-described sensorgrams showing the concentration of domain 11
against response at equilibrium (Req), binding to commercial IGF2 (red line), and binding to NusA-IGF2 (blue line). Req is shown as a percentage of the
maximum response (Rmax).
(E) HPLC chromatogram of purified IGF2.
(F) Changes in DNA replication in keratinocyte cell-type cultures upon addition of NusA-derived IGF2 (50 and 100 ng/ml) or commercial IGF2 (100 ng/
ml); bars indicate estimated error.bind to a more native-like IGF2R, it was decided to pro-
ceed with immobilized domains 10–13. The presence of
domain 13 enhances IGF2 affinity by slowing its rate of re-
lease from the receptor compared to use of domain 11
alone (Devi et al., 1998; Linnell et al., 2001) and shows
a greater degree of specificity for correctly folded IGF2.
However, using IGF2 as an analyte has resulted in associ-
ated problems, as this protein has a tendency to nonspe-
cifically associate with the sensor chip. To account for
this, a null I1572T domain 10–13 mutant was used as a neg-
ative control (Zaccheo et al., 2006). The final assay there-
fore utilized a biotinylated 10–13 construct derived from
293T human embryonic kidney cells as the immobilized li-
gand. The receptor was captured via streptavidin to the
sensor chip, and recombinant IGF2 was used as the ana-
lyte. The fusion protein displays slightly faster ‘‘on’’ and
‘‘off’’ rate kinetics and may reflect the higher affinity of
the NusA-derived IGF2 for this IGF2R fragment. Alterna-
tively, the binding kinetics may have been affected by sub-
tle pH changes to the mobile phase due to the sample be-
ing differently buffered or due to the presence of additional
residues at the N terminus compared to commercial IGF2.
The presence of additional residues at the N terminus is un-
likely to substantially affect the structure or activity of IGF2
compared to the native protein. Structural studies on long-
Arg3-IGF1, an IGF1 analog with a 13 residue N-terminal
extension, indicate that the structure of the mutant is es-1068 Structure 15, 1065–1078, September 2007 ª2007 Elseviersentially the same as the native protein, although minor
changes may subtly modulate binding affinity (Laajoki
et al., 2000). N-terminally modified IGF analogs often dis-
play increased biological activity compared to the native
IGF, but this is primarily due to a lower binding affinity for
IGFBPs (Francis et al., 1992).
The biological activity of IGF2 is mediated primarily
through the IGF1 receptor (IGF1R) (Ullrich et al., 1986).
Upon binding, IGF1R phosphorylates a variety of proteins,
leading to a diverse range of signal transduction events
resulting in cell proliferation, growth, and DNA synthesis.
By monitoring changes in the incorporation of tritiated
thymidine into the cell upon addition of IGF2, the in vivo
biological activity of recombinant IGF2 can be tested
and compared to that of commercial IGF2. As expected,
recombinant IGF2 gave a response similar to that of
commercial IGF2, giving a maximal 2-fold increase over
the control (no added IGF2) (Figure 2F). Taken together,
the analytical and biological data suggest that IGF2
expressed and purified as a NusA fusion is correctly
folded and active.
Recombinant domain 11 was refolded and purified by
using the protocol of Brown et al. (2002), and binding ki-
netics to immobilized commercial IGF2 were assessed
by using SPR over the pH range 3.5–8.5. Domain 11 ex-
hibited similar IGF2 binding over the pH range 5.5–8.5
and exhibited optimal binding at pH 5.5 (data not shown).Ltd All rights reserved
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Interaction of IGF2 with IGF2R Domain 11Figure 3. Backbone Dynamics and Solution Structure of IGF2R Domain 11
(A) Ensemble of 20 representative structures of domain 11.
(B) Superimposition of the ribbon representations of the solution structure (red) and the 1.4 A˚ crystal structure (blue; 1GP0 [Brown et al., 2002]) of
domain 11 with secondary structures labeled.
(C) [1H]-15N NOE values for IGF2R domain 11 acquired at 600 MHz; bars indicate estimated errors. Secondary structure elements appear above;
b strands are designated as black bars. Loop regions forming the IGF2 binding site are red for the AB loop, blue for the CD loop, and green for
the FG loop. F1567 and I1572, critical for IGF2 binding, are highlighted in magenta.
(D) Ribbon representation of domain 11 colored coded by [1H]-15N NOE. Residues are interpolated continuously from 1.2 (red) to 0.89 (blue). Res-
idues for which no order parameters were obtained are gray.Solution Structure of IGF2R Domain 11
To map the interaction site of IGF2 on domain 11, and as
a first step toward studying the structure and dynamics of
the complex in solution, heteronuclear NMR was used to
study domain 11 in isolation and then in complex with
IGF2. The assignment of the 1H, 13C, and 15N resonances
of domain 11 were obtained by using standard triple res-
onance experiments, and the solution structure was de-
termined by using dihedral angles, hydrogen bonds, and
NOEs from 3D 15N-edited NOESY-HSQC, a 2D 1H-1H NO-
ESY, and a simultaneous 15N/13C-edited NOESY. The final
20 structures chosen to represent the ensemble of NMR
structures (Figure 3A) were consistent with both experi-
mental data and standard covalent geometry, displaying
no violations greater than 0.5 A˚ for distance restraints or
5 for dihedral angles. Details of the final set of structural
restraints and their violations within the final ensemble
are listed in Table 1.Structure 15, 1065–1078, SThe core of domain 11 is well defined, with a backbone
rmsd from the mean over the regular secondary structure
elements of 0.54 A˚ for the ensemble of structures. As ex-
pected, the solution structure of a nine-stranded flattened
b barrel (bA–bI) is held together by four disulphide bonds
and is highly similar to the 1.4 A˚ crystal structure of domain
11 solved at pH 8.5 (1GP0) (Brown et al., 2002), with a
backbone rmsd over the secondary structure elements
of 1.0 A˚ (Figure 3B). Minor differences in the solution and
crystal structures are observed in the N-terminal b hairpin
cap.
Targeted alanine mutagenesis of solvent-exposed resi-
dues in the cavity established that the principal IGF2 bind-
ing core is formed by hydrophobic residues in the CD loop,
with additional residues in the FG loop also contributing to
binding (Zaccheo et al., 2006). Interestingly, the loop re-
gions in the putative IGF2 binding site, in particular the
AB and FG loops, display a heightened degree of disordereptember 2007 ª2007 Elsevier Ltd All rights reserved 1069
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Interaction of IGF2 with IGF2R Domain 11in the ensemble of calculated structures. Heightened ther-
mal B factors in the crystal structure, although not as
marked as suggested by the solution structure ensemble,
suggest that these regions may have a degree of flexibility
that may be important for IGF2 recognition and binding.
Similarly, B factors suggest that the CD loop maintains
a degree of rigidity, although crystal packing could
account for the structuring of this loop. Therefore, the
backbone dynamics of domain 11 were analyzed to
provide information about the mobility of these regions
in solution. Heteronuclear NOEs are more sensitive to
the effects of internal motion than T1 or T2; hence, regions
Table 1. Structural Statistics on the Final Set of
Simulated Annealing Structures of IGF2R Domain 11
Total NOE restraints 2200
Intraresidue NOEs 800
Sequential/medium
NOEs (residue i to
i+1,2,3,4,5)
746
Long-range NOEs 654
Dihedral angle restraints
Backbone F and c 206
Hydrogen-bond restraints 60
Energies (kcal mol1)
ENOE 3.34 ± 0.397
EDIHE 6.67 ± 4.853
EVDW 566.816 ± 20.878
EELEC 5530.56 ± 73.748
Rmsd from ideal geometry
Bonds (A˚) 0.0048 ± 0.0001
Angles () 0.5829 ± 0.0141
Improper () 0.5653 ± 0.0194
Rmsd to mean for
backbone atoms
0.54 ± 0.12a
Rmsd to mean for heavy atoms 1.52 ± 0.22a
Average number of NOE
violations
>0.3 A˚ (per structure) 11
>0.5 A˚ (per structure) 0
Ramachandran plot regionsb
Most favored (%) 78.3
Additionally allowed (%) 17.4
Generously allowed (%) 3.4
Disallowed (%) 0.9
a Rmsd from mean structure calculated over residues 1516–
1520, 1525–1531, 1538–1542, 1546–1551, 1562–1568,
1572–1577, 1582–1584, 1587–1592, 1596–1598, 1604–
1615, 1625–1630, and 1632–1640.
b Calculated with PROCHECK-NMR (Laskowski et al., 1996).1070 Structure 15, 1065–1078, September 2007 ª2007 Elsevierwith contributions to their relaxation from internal dynam-
ics on the sub-nanosecond timescale are more apparent
from inspection of the plot of [1H]-15N NOE values
(Figure 3C). Steady-state heteronuclear [1H]-15N NOEs
were obtained for 129 of the 136 assigned (95%) non-pro-
line 15N nuclei by analysis of the 2D 1H-15N correlation
spectra. Missing residues were invariably located in loop
segments of the structure, and their absence is attributed
to broadening by solvent exchange. In general, residues in
the secondary structure displayed NOEs > 0.7, while
those in the more flexible termini and loop regions exhibit
lower than average NOE values (Figure 3C). As expected,
the loops that compose the IGF2 binding site all display
decreased NOE values, indicative of fast motions on the
nanosecond to picosecond timescales. In particular, the
AB loop, which acts to modulate IGF2 binding affinity, dis-
plays dramatically decreased NOE values, indicating sub-
stantial motions (Figure 3D). Mobility of this region would
allow the IGF2 binding site to adapt to an optimal confor-
mation for binding IGF2 and modulate affinity. Interest-
ingly, the key domain 11 residues critical for IGF2 binding,
F1567 and I1572, both display NOE values > 0.7. In gen-
eral, this region shows higher average NOE values (0.6)
than the other loops in the binding site, indicating an over-
all restriction of motion in solution. These findings are con-
sistent with current theories of a rigid binding site flanked
by flexible loops (Keskin et al., 2005). The core binding
pocket, formed primarily by F1567 and I1572, is fairly rigid,
which allows for ligand recognition, docking, and solvent
exclusion. Flanking the binding pocket are flexible loops,
the so-called second sphere or O-ring residues, that fur-
ther select for the correct ligand and modulate binding.
Mapping the Binding Site of IGF2 to the Solution
Structure of Domain 11
Due to its inherent flexibility and tendency to aggregate,
IGF2 is notoriously difficult to work with at pH values
above 3.0 and at millimolar concentrations. Previous ob-
servations also indicate that domain 11 has a tendency
to precipitate at pH values below 4.5, necessitating that
the complex be prepared at dilute conditions. Therefore,
as a first step toward solving the structure of the complex
and to gain detailed insight into the molecular interface at
the atomic level, NMR titrations were performed with 15N-
labeled domain 11 and IGF2. Mapping the IGF2 binding
site on domain 11 was achieved by using chemical shift
perturbations in 1H-15N HSQC spectra on domain 11 in-
duced by the binding of IGF2 at 25C and pH 5.5. To follow
the effect of IGF2 binding to domain 11 in solution, a 2D
1H-15N HQSC spectrum on a 1:1 mixture of unlabeled hu-
man IGF2:uniformly 15N-labeled domain 11 was recorded.
A large number of peaks in the HSQC spectrum of domain
11 remain unperturbed upon addition of IGF2, but many
are shifted significantly (Figure 4A). Where possible, the
assignment of shifted peaks was made by using 15N
TOCSY-HSQC and 15N NOESY-HSQC spectra. However,
due to the low protein concentration (0.1 mM), high-
resolution spectra could not be obtained in a reasonable
time for a complex of this size. Therefore, the smallLtd All rights reserved
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Interaction of IGF2 with IGF2R Domain 11Figure 4. NMR Titration of IGF2R Domain 11 with IGF2
(A) 1H-15N HSQC of IGF2R domain 11 in the absence (black) and presence (red) of IGF2. The insert panel shows an expanded view of the boxed
region.
(B) Chemical shift perturbations in domain 11 due to binding to IGF2 mapped onto a molecular surface representation. Residues with shift perturba-
tions > 0.05 ppm are red, and residues with shift perturbations < 0.05 ppm are orange. Blue indicates NH resonances that broaden and disappear
upon IGF2 binding, and gray indicates little or no change in chemical shift upon binding. Residue G1568 is not visible in this orientation of the surface.number of shifted peaks that could be not be assigned un-
ambiguously, but were still close enough to the corre-
sponding peak in free domain 11 to be assignable, were
classified as either ‘‘intermediate’’ (<0.05 ppm) or ‘‘large’’
(>0.05 ppm). Those peaks that broadened beyond detec-
tion or could not be assigned by comparison to the un-
bound spectrum were classified as ‘‘disappeared.’’ The
greatest concentration of perturbed residues is located
in the AB (K1545), CD (G1568, T1570, R1571, I1572),
and FG (G1595, S1600, G1603, L1604) loop regions,
which form a distinct patch on the structure of domain
11 (Figure 4B). Importantly, this group of residues includes
I1572, mutation of which abolishes IGF2 binding to do-
main 11 (Linnell et al., 2001). This patch also correlates
well with the solvent-exposed hydrophobic cavity previ-
ously speculated to be the IGF2 binding site (Brown
et al., 2002) and shown by mutagenesis to be important
(Zaccheo et al., 2006). Several residues surrounding this
patch are also perturbed upon IGF2 binding (C1559,
K1576, G1595, Y1606, T1633) and are shown in
Figure 4B. The remaining residues that show chemical
shift changes are scattered across the protein structure
or buried within the protein interior. Such shifts observed
outside the binding region may be caused by subtle struc-
tural rearrangements induced upon binding or by second-
ary effects, such as allostery or changes in mobility upon
binding, and do not necessarily indicate direct binding of
IGF2 to domain 11.
IGF2R:IGF2 Docking
HADDOCK v1.3 (Dominguez et al., 2003) was used to
dock IGF2 with domain 11 by using a combination of
NMR titration and mutagenesis data from both domainStructure 15, 1065–107811 and IGF2. For domain 11, the active residues high-
lighted in Figure 4 were filtered by using relative solvent
accessibility. Those residues with less than 50%
solvent accessibility (C1559, K1576, G1595, S1600,
L1604, and Y1606) were excluded from the calculations.
Passive residues were then defined as surface neighbors
of the active residues, also with high solvent accessibility
(>50%).
New binding studies have generated 14 different IGF2
homologs and identified 3 residues as critical for binding,
T16, F19, and L53 (Delaine et al., 2007). A fourth residue,
D52, also showed a 20-fold reduction in binding when mu-
tated to a bulkier, oppositely charged lysine. Previous
studies utilizing a triple IGF2 mutant (F48T, R49S, S50I)
and a double IGF2 mutant (A54R, L55R) also showed no
binding to rat placental membranes, suggesting that addi-
tional residues are involved in IGF2R binding. However,
others have reported only an 18-fold reduction in binding
to cell-surface-expressed IGF2R with an F48E mutant
(Burgisser et al., 1991), and, more recently, both BIAcore
analysis and rat placental membrane receptor binding as-
says have shown that the single A54R and L55R mutations
have only a 3- to 4-fold reduction in binding. Such differ-
ences between the measured affinities may be due to
the experimental approach used; measurements have
been determined both by radioimmunoassays and SPR,
and the use of crude preparations of the entire IGF2R
may be affecting IGF2 binding (Devi et al., 1998; Linnell
et al., 2001). Nonetheless, whereas A54 and L55 are
thought to play some role in IGF2R specificity, conserva-
tion of F48, R49, and S50 between IGFI and IGF2 means
that they may be less likely to be key residues for IGF2R
selectivity (Forbes et al., 2001)., September 2007 ª2007 Elsevier Ltd All rights reserved 1071
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IGF2 Mutagenesis Data
To gain structural insight into the role of different resi-
dues in binding, two docking runs were performed.
For the first run, all of the existing IGF2 residues shown
to affect binding to IGF2R were set to active (with the
exception of T16 and L55, which are not >50% solvent
exposed), while the second run used only those IGF2
residues shown to be critical for binding to IGF2R do-
main 11 as active (Table 2). These residues were used
to generate ambiguous interaction restraints (AIRs) be-
tween the average minimized NMR structures of both
protein partners. A total of 10,000 rigid-body dockings
were performed for each run by using the AIRs and in-
termolecular energy. The 200 lowest-energy structures,
based on intermolecular van der Waals, electrostatic,
and AIR energy terms, were then refined in water and
clustered as a function of their backbone rmsd (2.5 A˚
cutoff) from the lowest-energy structure (Table S1, see
the Supplemental Data available with this article online).
A total of nine clusters with similar energies was gener-
Table 2. List of Active and Passive Residues Used
to Define the Ambiguous Interaction Restraints
for the Docking of IGF2 with IGF2R Domain 11
Run 1
IGF2
Active residues F19, F48, R49, S50, L53, A54
Passive residues Y2, T7, N15, D18,
E44, D52, E57, T58
Flexible segments 1–12, 28–43, 49–54, and 62–67
IGF2R domain 11
Active residues E1544, K1545, T1570,
R1571, I1572, G1603, T1633
Passive residues S1543, Q1569, K1601,
S1602, Q1632
Flexible segments 1543–1547, 1567–1574,
1595–1604, and 1630–1633
Run 2
IGF2
Active residues F19, L53
Passive residues N15, D18, D52, E57
Flexible segments 1–12, 28–43, 49–54, and 62–67
IGF2R domain 11
Active residues E1544, K1545, T1570,
R1571, I1572, G1603, T1633
Passive residues S1543, Q1569,
K1601, S1602, Q1632
Flexible segments 1543–1547, 1567–1574,
1595–1604, and 1630–1633
Active residues for IGF2 were obtained from structural and
mutagenesis studies (Sakano et al., 1991; Torres et al.,
1995; Forbes et al., 2001; Delaine et al., 2007).1072 Structure 15, 1065–1078, September 2007 ª2007 Elsevieated from the first run. On inspection, these 9 clusters
were clearly differentiated into two overall topologies
containing 21 structures (clusters 1–3) and 165 struc-
tures (clusters 4–9) (Figure S1). The lowest-energy struc-
tures for the two groups are shown in Figures 5A and
5B, respectively. The average buried surface area of
the 21 structures in clusters 1–3 is 1385 A˚2. In this to-
pology, helix a3 of IGF2 forms interactions with the
FG loop residues of domain 11 (Figure 5A). IGF2 resi-
dues F48 and R49 are found to interact with the FG
loop residues of domain 11 and, to a lesser extent,
with residues of the CD loop. However, F19, D52, and
L53 do not interact with domain 11 in these models
but are solvent exposed. The second topology (clusters
4–9) contains the most structures and has a higher av-
erage buried surface area, 1578 A˚2, and reduced inter-
action energies. In this solution, IGF2 is rotated 90
in the domain 11 binding pocket; residues in helix a2
of IGF2 form extensive contacts with the FG loop resi-
dues of domain 11, while IGF2 helix a3 residues interact
with the AB loop. The functionally important IGF2 resi-
dues F19, D52, and L53 in this model are found to
form contacts with the domain 11 FG loop residues
P1599 and S1600 (Figure 5B). However, in this case,
F48 and R49 do not interact with domain 11. Therefore,
it is clearly impossible to mutually satisfy all of these
residues at a docking interface of a domain defined by
the NMR studies and current mutagenesis data.
Docking Studies Utilizing Only Residues Critical
for Domain 11 Binding
When only surface-exposed IGF2 residues critical for
IGF2R domain 11 binding (F19, D52, and L53) were in-
cluded in the docking calculation, two clusters were iden-
tified in the family of 200 water-refined structures when
compared to the lowest-energy structure when using
a 2.5 A˚ rmsd cutoff. The two clusters were evenly popu-
lated (98 and 89 structures) with similar average energies,
low intermolecular energy values, low numbers of viola-
tions, and extensive surface area burial (Table S1). The
protein-protein buried surface area for the final 200 wa-
ter-refined structures ranges from 900 to 1782 A˚2, with
an average of 1257 A˚2 for cluster 1 and 1200 A˚2 for cluster
2, which is within the most common range of 1600 ± 400
A˚2 seen in biological protein-protein complexes (Lo Conte
et al., 1999). A rotation of 20 of IGF2 in the binding
pocket differentiates the lowest-energy structures from
both clusters. The lowest-energy solution of clusters 1
and 2 are shown in Figures 5C and 5D, respectively. In
both cases, IGF2 wraps around the IGF2 binding site of
domain 11, forming an extensive binding interface of
1774 A˚2. As observed for other complexes with exten-
sive binding interfaces (Nooren and Thornton, 2003), large
conformational changes are observed in the complex, pri-
marily in the loop regions of IGF2 at the binding interface.
IGF2 residue F19 forms extensive interactions with resi-
dues in the CD and FG loops of domain 11 such as
T1570, I1572, P1597, P1599, and Y1606. Interestingly,
mutational studies have shown that residues with the
r Ltd All rights reserved
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Interaction of IGF2 with IGF2R Domain 11Figure 5. Structural Models of Domain 11-IGF2 Complexes Generated by HADDOCK
(A) Lowest-energy structures from clusters 1–3 of the domain 11-IGF2 complex generated by using all existing IGF2 mutagenesis data.
(B) Lowest-energy structures from clusters 4–9 of the domain 11-IGF2 complex generated by using all existing IGF2 mutagenesis data.
(C and D) Lowest-energy structural model from (C) cluster 1 and (D) cluster 2 of the domain 11-IGF2 complex generated by using only IGF2 residues
F19 and L53. Domain 11 is shown in surface representation; the core IGF2 binding site is highlighted in blue. Key residues involved in the interaction
are rendered as sticks. E1544, shown to negatively regulate IGF2 binding, is shown in red.greatest contribution to IGF2 binding are the CD loop hy-
drophobic residues F1567, T1570, and I1572 (Zaccheo
et al., 2006). These residues form part of the hydrophobic
patch highlighted by the crystal structure of domain 11
and, in both models, all undergo extensive burial upon
binding, with T1570 and I1572 becoming almost com-
pletely buried. T1570 may also play an important role in
stabilizing the interaction. Mutation of T1570 to alanine re-
sults in a 9-fold reduction in the affinity of domain 11 for
IGF2 compared to the wild-type (Zaccheo et al., 2006).
This effect is principally due to a faster dissociation rate
and could be due, in part, to the removal of hydrogen
bonds that would otherwise stabilize the complex. Inter-
estingly, this residue is also found to consistently form hy-
drogen bonds with IGF2 residues V20 and E57 in the
docking solutions. Models 5C and 5D also validate other
functional data. For example, the specificity of domain
11 for IGF2 over the highly homologous IGF1 has been at-
tributed, at least in part, to residues A54 and L55 (Sakano
et al., 1991 and Torres et al., 1995). In models 5C and 5D,
both residues undergo extensive burial by interaction with
AB loop residues. The equivalent residues in IGF1 are
charged arginines (R55 and R56). Replacement of the hy-
drophobic IGF2 residues with bulky charged residues may
result in unfavorable contacts with residues in the AB loopStructure 15, 1065–1078,and would account for the observed lower binding affinity
of IGF1 (Linnell et al., 2001; Zaccheo et al., 2006).
Recent mutagenesis studies on the IGF2 binding site of
domain 11 have shown that replacement of Glu with Lys or
Arg at position 1544 of domain 11 results in a 6- to 7-fold
increase in IGF2 binding affinity (Zaccheo et al., 2006).
Close examination of our models goes some way toward
explaining these findings. In the ensemble of models,
L53, A54, and E57 of IGF2 form extensive contacts with
the AB loop of domain 11, while the side chain of K1545
consistently forms hydrogen bonds with the backbone
carbonyl groups of D52 and L53. In our preferred model,
5D, helix a2 is brought closer to both E1544 and K1545,
and a salt bridge between K1545 and E57 is distinguish-
able. Replacing E1544 with a Lys/Arg combined with
a subtle rearrangement of IGF2 in the binding site would
allow the longer basic side chain to come into close con-
tact with negatively charged residues on helix a3 of IGF2,
particularly D52, allowing additional interactions to form,
further stabilizing the complex (Figure 5D). The steady-
state heteronuclear [1H]-15N NOE data indicate that resi-
dues in the AB loop, particularly E1544 and K1545, are
highly flexible and unconstrained. IGFs are also known
to be highly dynamic in nature, with a considerable degree
of flexibility in the loop regions and even conformationalSeptember 2007 ª2007 Elsevier Ltd All rights reserved 1073
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Interaction of IGF2 with IGF2R Domain 11Figure 6. Computational Model of the IGF2R Domain 11-IGF2 Complex
(A) The core of the interface is shown in blue. Key IGF2 residues involved in the interaction are rendered as sticks. The negative regulator E1544 is
highlighted in red.
(B) Rotated view of the IGF2 binding site showing insertion of the flexible loop of IGF2 into the second hydrophobic patch of domain 11 identified from
the crystal structure incorporating residues V1584, V1587, V1591, V1613, M1625, I1627, L1629, K1631, C1634, and F1637 (Brown et al., 2002) high-
lighted in green.averaging within the helices (Laajoki et al., 2000). These
observations suggest that such rearrangements are very
likely in both interacting partners.
Analysis of domain 11 sequences from different verte-
brates reveals the presence of additional variable residues
(S1543, Q1569, R1571, and S1596) in and around the IGF2
binding site (Figure 1C). Classed as O-ring residues, these
groups protect hydrophobic residues in the binding
pocket from solvent and stabilize the interaction via hydro-
gen bonds and salt bridges, thereby slowing dissociation
(Li et al., 2004; Keskin et al., 2005). Close analysis of the
docking solutions shows that the majority of these variable
O-ring residues consistently form hydrogen bonds or elec-
trostatic interactions with IGF2 residues. In particular,
Q1569 and S1596 of domain 11 interact with E57 and
D23, respectively, in over 50% of the ten best structures.
Of the other variable O-ring residues, R1571 forms a
variety of interactions within the ensemble of structures,
interacting primarily with V20, R24, and E57. However,
S1543, on the AB loop, forms very few hydrogen-bond
or electrostatic interactions with IGF2 in our model and
may have a greater role in protecting hydrophobic resi-
dues in the binding pocket from solvent attack.
Comparison with Previous Docking Studies
Recently, the interaction between IGF2 and IGF2R domain
11 was modeled in silico using the 3D-Dock suite of pro-
grams (Roche et al., 2006). The proteins were docked as
rigid bodies by using shape complementarity, and the so-
lutions were filtered using the key residue I1572 of IGF2R.
An additional filtering step retained only complexes in
which F48 and R49 of IGF2 contacted IGF2R. The Roche
model has a similar sized interface to our models (1790 A˚2)
(Figure 6); however, IGF2 is rotated 45 and 100 in the
binding pocket relative to models 5C and 5D, respectively.
IGF2R domain 11 residues in the AB and CD loops (Y1542,
S1543, G1546, F1567, G1568, T1570, I1572, S1596,
P1597, and P1599) form the core of the interaction, inter-1074 Structure 15, 1065–1078, September 2007 ª2007 Elsevieacting primarily with IGF2 residues in helix a2 (Figure 6A).
For IGF2 residues, use of F48 and R49 as filters precluded
docked models having F19 or L53 at the interface. Some
residues that form part of a second hydrophobic patch
on domain 11 (Brown et al., 2002) are also buried
(L1626, I1627, S1628, L1629, K1631, and C1634). These
residues interact mainly with the long, flexible, highly
charged loop (S29-R40) of IGF2 (Figure 6B). Several po-
tential hydrogen bonds exist between the IGF2 loop resi-
dues and domain 11 residues, including E1544. Since
publication of the Roche model, Zaccheo et al. (2006) ob-
served the effects of replacing E1544 with other side
chains; replacement with a larger basic side chain might
introduce unfavorable interactions with R30 and R38 of
IGF2 in the Roche model, which would be expected to
lower, rather than raise, IGF2 binding affinity, as was ob-
served experimentally.
Conclusions
Studying the interaction of IGF2 with its binding partners is
notoriously difficult due to its tendency to aggregate in so-
lution and to its highly dynamic nature. Unlike previous
IGF2 purification protocols, we have used a NusA fusion
strategy for the large-scale production of human IGF2
that does not require complex and time-consuming re-
folding and purification steps. The availability of suitable
quantities of IGF2 has allowed the application of NMR
chemical shift mapping experiments to identify the resi-
dues of domain 11 involved in the binding interface with
IGF2. Mapping the chemical shift perturbations onto the
solution structure of domain 11 reveals a single patch
that corresponds well with the putative hydrophobic bind-
ing site predicted by mutagenesis and structural data.
Subsequently, protein docking with the program HAD-
DOCK was used to calculate structural models for the
complex. Two docking runs were performed to assess
the role of the residues identified to be important for bind-
ing. The first used all of the existing mutagenesis datar Ltd All rights reserved
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the second incorporated only IGF2 residues recently
shown to be critical for binding to IGF2R domain 11.
When all of the existing IGF2 data were added to the dock-
ing calculation, the final solutions did not converge and
yielded two clusters that failed to show interactions be-
tween the full set of residues included for IGF2. A single
solution was obtained when only IGF2 residues shown
to be critical for binding to IGF2R domain 11 were used,
which concurs with the main characteristics found at the
interface of a typical biological complex and satisfies ex-
isting mutagenesis and structural data on the complex.
In this model, IGF2 residues T16, F19, D52, L53, A54,
and E57 fit into the domain 11 binding groove and form ex-
tensive contacts with the AB, CD, and FG loops of domain
11. The models indicate that hydrophobic interactions
most likely drive docking, with additional electrostatic in-
teractions stabilizing the final conformation.
EXPERIMENTAL PROCEDURES
IGF2 Cloning, Expression, and Purification
The 204 bp cDNA encoding mature IGF2 was amplified by polymerase
chain reaction (PCR), by using 50-AAAAAAAACCATGGCAGCTTACC
GCCCCAGTGAGA-30 and 50-AAAAAACTCGAGTCACTCGGACTTGG
CGGGGG-30 as primers. The PCR product was double digested with
NcoI and XhoI and was cloned into the pETM-60 expression vector
(EMBL) (De Marco et al., 2004). The authenticity of the clone construct
was confirmed by nucleotide sequencing.
E. coli BL21 (DE3) (Novagen) with the desired plasmid was grown in
Luria-Bertani medium at 37C supplemented with 100 mg ml1 kana-
mycin (Melford). When the OD600 reached 0.8–0.9, protein expression
was induced with the addition of 1 mM IPTG (Melford). The culture was
incubated for an additional 5–6 hr with vigorous aeration (225 rpm) at
25C before the cells were harvested by centrifugation (6000 3 g,
10 min, 4C). The cell pellet was resuspended in lysis buffer (50 mM
Tris-HCl [pH 8.8], 0.5 M NaCl, 0.05% Triton X-100, 10% glycerol) sup-
plemented with a complete protease inhibitor cocktail tablet (Boeh-
ringer Mannheim, Germany). Soluble protein was extracted by sonica-
tion (103, 30 s pulse on; 60 s pulse off) in an ice/salt/water bath. Cell
debris was removed by centrifugation (18,0003 g, 20 min, 4C) to yield
a supernatant containing the soluble protein. The soluble protein ex-
tract was then applied to a gravity column packed with Fast Flow Che-
lating Sepharose (GE Healthcare) loaded with nickel sulfate (Sigma).
After extensive washing with lysis buffer minus Triton X-100, the col-
umn was washed in a low-salt buffer (50 mM Tris-HCl [pH 8.0],
0.15 M NaCl, 5 mM imidazole) before the recombinant proteins were
eluted in 50 mM Tris-HCl (pH 7.0), 0.15 M NaCl, 500 mM imidazole.
The eluted NusA-IGF2 fractions identified by SDS-PAGE were pooled,
and NusA was cleaved off the recombinant protein by TEV digestion
(1 U/mg fusion protein; Novagen). IGF2 was further purified by using
a Superdex 26/60 75pg (GE Healthcare) running 20 mM Tris-HCl
(pH 7.0), 0.15 M NaCl, and 1 M urea on an A¨KTA FPLC system (GE
Healthcare). Prior to lyophilization, IGF2 was desalted and concen-
trated on C4 reverse-phase beads (Phenomenex). After binding, the
beads were extensively washed with increasing concentrations of ace-
tonitrile containing 0.04% trifluoroacetic acid before elution with 50%
acetonitrile and 0.04% trifluoroacetic acid. The purity was determined
to be greater than 95%, as judged by SDS-PAGE.
Expression and Purification of Mini-IGF2R Constructs
A pET22b expression vector (Novagen, Madison) encoding domain 11,
nucleotides 4522–4945 of IGF2R, was used to generate recombinant
His6-tagged protein in E. coli strain BL21 (DE3) as inclusion bodies,
and the protein was refolded according to standard protocols (BrownStructure 15, 1065–1078et al., 2002). After refolding, soluble protein was concentrated by ultra-
filtration and further purified using a Superdex 26/60 75pg column (GE
Healthcare) running 20 mM Tris (pH 8.0), 0.1 M NaCl. 15N/13C isotope
labeling was performed in M9 minimal medium containing 1 g/l
15NH4Cl and/or 2 g/l
13C-glucose (99.9%; Cambridge Isotope Labora-
tories). NMR samples typically contained 1 mM domain 11 in 0.6 ml of
20 mM sodium acetate (pH 5.5), 1 mM EDTA, 1 mM benzamidine, and
100 mM NaN3 in 95% H2O/5% D2O. Biotinylated IGF2R domain 11 and
the null I1572T mutant were expressed in Pichia pastoris and purified
by using existing protocols (Zaccheo et al., 2006). IGF2R domains
10–13 and the null I1572T mutant were expressed in human
embryonic kidney 293T cells and purified by using existing protocols
(Linnell et al., 2001). Protein concentrations were determined by mea-
suring the absorbance at 280 nm.
Recombinant IGF2R domain 11 activity was analyzed as described
previously (Brown et al., 2002), and the null I1572T mutant form of do-
mains 10–13 used as a negative control. To assess the affect of pH on
IGF2 binding to domain 11, domain 11 was run over immobilized
biotinylated IGF2 (GroPep) in 10 mM potassium phosphate, 150 mM
NaCl, 3 mM EDTA at pH 3.5, 4.5, 5.5, 6.5, 7.5, and 8.5.
High-Performance Liquid Chromatography
High-performance liquid chromatography (HPLC) was performed on
a Dionex HPLC ASI-100 automated sample injector, P680 HPLC
pump, and PDA-100 Photodiode array detector. Dionex Chromeleon
v.6.60 was used for data treatment. Protein samples were analyzed
on a Jupiter C4 4m Proteo reverse-phase column by using a linear gra-
dient from A (5% acetonitrile, 0.1% trifluoroacetic acetic acid) to B
(95% acetonitrile, 0.1% trifluoroacetic acetic acid) with a flow rate of
1 ml/min at 25C. The elution of IGF2 was monitored at 214 and 280 nm.
Biotinylation of NusA-IGF2
NusA-IGF2 was randomly biotinylated by using the labeling agent
biotinamidohexanoic acid 3-sulfo-N-hydroxysuccinide ester (BAC-
SulfoNHS) available in the BiotinTag micro-biotinylation kit (Sigma-
Aldrich, Dorset, UK). Biotinylation was performed in accordance with
the manufacturer’s instructions. Briefly, biotinylation was achieved
by mixing 5 ml freshly prepared 5 mg/ml BAC-SulfoNHS with 150 ml
10 mg/ml NusA-IGF2 solution in 0.1 M sodium phosphate buffer
(pH 7.2) (molar ratio of 13:3) and incubating with gentle stirring for
30 min at room temperature or for 2 hr at 2C–8C. The labeled protein
was separated from the unreacted biotinylation reagent by using the
provided Sephadex G-50 columns. Approximately 100 ml of the
labeled protein was recovered.
Surface Plasmon Resonance Analysis of Recombinant IGF2
Commercial biotinylated IGF2 (GroPep Ltd., Adelaide, Australia) and
biotinylated NusA-IGF2 were immobilized by affinity capture on
a streptavidin (SA) BIAcore sensor chip as described by Zaccheo
et al. (2006). Kinetic analysis by SPR was conducted on a BIAcore
3000 biosensor (BIAcore, Uppsala, Sweden) at 25C in HBS-EP
(10 mM HEPES [pH 7.4], 150 mM NaCl, 3 mM EDTA, 0.005% [v/v] sur-
factant P20) at a flow rate of 40 ml/min. Kinetic experiments were
performed as described by Zaccheo et al. (2006), whose experiments
consisted of a 200 s injection of domain 11, followed by a 300 s disso-
ciation phase in HBS-EP. For each domain 11 concentration, injections
were performed in duplicate and in a randomized order. BIAevaluation
software version 4.0.1 was used to determine kinetic parameters by
global fitting of sensorgrams to the two-state (conformational change)
binding model. Additionally, BIAevaluation was also used to calculate
the dissociation affinity constant (KD) by fitting the response of each
concentration at equilibrium to a steady-state affinity model.
For the analysis of purified IGF2, recombinant human biotinylated
IGF2R domain 11 or domains 10–13 were immobilized on a SA sensor
chip by affinity capture to SA, and15 mM solution of IGF2 was passed
over the chip at a flow rate of 20 ml/min. Each run had a 2.5 min injection
and a 5 min dissociation. Recombinant IGF2 (GroPep Ltd., Adelaide,, September 2007 ª2007 Elsevier Ltd All rights reserved 1075
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forms of domain 11 or domains 10–13 were used as negative controls.
Biological Cell Assay of NusA-Derived IGF2
IGF2 biological activity was assayed by monitoring 3H-thymidine in-
corporation. HaCaT human keratinocytes, a kind gift from Dr. A. Hague
(Department of Oral and Dental Science, University of Bristol, UK),
were grown in DMEM/F-12 (1:1) supplemented with 10% fetal bovine
serum (FBS), 0.5 mg/ml hydrocortisone, 50 IU/ml penicillin, 5 mg/ml
streptomycin, and 1 mM L-glutamine. Cells were seeded onto 12-
well plates, 23 104 per well, in growth media. After 24 hr, HaCaT cells
were serum starved for 24 hr and then treated with the various IGF2
constructs preincubated at room temperature in 500 ml serum-free me-
dium for 10 min. After an additional 24 hr, 1 mCi 3H-thymidine/well was
added, and the cells were incubated for 1 hr. Media were removed,
and cells were washed twice with PBS before fixation in 500 ml 5%
TCA for 20 min at 4C, followed by extraction in 400 ml 0.1 M NaOH
at 4C for 1 hr. Incorporation of 3H-thymidine was analyzed by scintil-
lation counting.
NMR Spectroscopy
All NMR data were acquired at 25C on a Varian 600 MHz INOVA spec-
trometer. Sequence-specific backbone resonance assignments were
made with 3D HNCA, HN(CO)CA, HNCACB, CBCA(CO)NH, HNCACO,
HNCO, and HCACO data sets. Assignments were performed in an it-
erative fashion by using the program MARS (Jung and Zweckstetter,
2004) and manual assignment within SPARKY. Side chain resonance
assignments were made with CCC-TOCSY-NNH, HCC-TOCSY-
NNH, HCCH-TOCSY, and 15N-edited TOCSY data sets (12.1, 12.1,
15.6, and 50 ms mixing time, respectively). Aromatic side chain assign-
ments were obtained by using intraresidue NOEs between the bCH2
and/or a-proton and the aromatic ring protons in 2D 1H-1H NOESY
spectra and a 3D 13C-edited NOESY spectrum. Proton chemical shifts
were referenced with respect to the water signal relative to DSS. NOE
distance restraints were obtained by analysis of simultaneous 3D
15N/13C-edited NOESY spectrum (100 ms mixing time), 15N NOESY-
HSQC spectra (100, 150, and 200 ms mixing times), and a 2D 1H-1H
NOESY (100 and 175 ms mixing times). (For an overview of the exper-
iments used, see Cavanagh et al. [1995].) Steady-state heteronuclear
[1H]-15N NOEs were determined from two spectra recorded with pro-
ton broadband irradiation with a saturation time of 5 s and a recycle de-
lay of 7 s and in the absence of proton saturation with a recycle delay of
12 s (Farrow et al., 1994). The value of the steady-state NOE was cal-
culated as the average ratio of peak intensities in the presence and ab-
sence of proton saturation.
Structure Calculation
Each NOE was assigned to one of four restraint distances based on the
peak intensity: 1.8–2.8 A˚, 1.8–3.3 A˚, 1.8–5.0 A˚, and 1.8–6.0 A˚, corre-
sponding to strong, medium, weak, and very weak NOEs, respectively.
Distances involving methyl groups, aromatic ring protons, and non-
stereospecifically assigned methylene protons were represented as
a (Sr6)1/6 sum. Backbone dihedral angles f and c were predicted
from 15N, 13Ca,
13Cb,
13CO, and 1Ha chemical shifts by using TALOS
(Cornilescu et al., 1999). Dihedral angles were restrained to ±30 and
±50 for a helices and b strands, respectively. For hydrogen-bond dis-
tance constraints, the NH-O distance was set between lower- and up-
per-bound distance bonds of 1.5 and 2.8 A˚, and the N-O distances
were set to lower and upper distance bounds of 2.4 and 3.5 A˚, respec-
tively. Structures were calculated with CNS v1.1 (Bru¨nger et al., 1998),
by using the default simulated annealing protocol starting from random
extended structures. The final ensemble of structures was further re-
fined in water by using the final set of restraints, and the quality of
the structures was checked by using the program PROCHECK-NMR
(Laskowski et al., 1996). Figures were generated with PyMol (DeLano,
2002).1076 Structure 15, 1065–1078, September 2007 ª2007 ElsevieIGF2 Titration to 15N Domain 11
Binding of unlabeled IGF2 to 15N-labeled domain 11 was followed by
chemical shift perturbation in 1H-15N HSQC spectra. Samples were
0.5 mM in 20 mM sodium acetate (pH 5.5), 1 mM EDTA, 1 mM ben-
zamidine, and 100 mM NaN3 in 95% H2O/5% D2O. The complex was
prepared by dissolving lyophilized IGF2 to a final concentration of
0.5 mM in 600 ml 0.5 mM domain 11. Sample pH was adjusted to
5.5 prior to NMR. Spectra were recorded at 25C and 34C. Typically,
2D 1H-15N HSQC spectra were acquired with 512 complex 1H points
and 256 complex 15N points with 40 scans per increment and spectral
widths of 7000 Hz in 1H and 2000 Hz in 15N.
Docking
Docking of the domain 11-IGF2 complex was performed by using the
software HADDOCK v1.3 (Dominguez et al., 2003) in combination with
CNS v1.1 (Bru¨nger et al., 1998) based on the chemical shift perturba-
tion data observed for domain 11 upon complex formation. The start-
ing structures for the docking were the average minimized NMR struc-
tures of domain 11 and IGF2 (PDB code: 1IGL) (Torres et al., 1995).
Domain 11 active and passive residues for HADDOCK were based
on the chemical shift perturbation data and solvent accessibility as cal-
culated by VADAR (Willard et al., 2003) (Table 2). Active residues were
defined as having a chemical shift perturbation upon complex forma-
tion greater than 0.05 ppm with an average relative solvent accessibil-
ity (plus standard deviation) higher than 50%. All amino acids neigh-
boring the active residues with a high solvent accessibility (>50%)
were defined as passive residues. A 2 A˚ distance was used to define
the ambiguous interaction restraints (AIRs). Two docking runs were
performed with either all the residues shown to affect binding set as
active for docking or just those shown to affect binding to IGF2R do-
main 11 (Table 2). Residues 1–12, 28–43, 49–54, and 62–67 of IGF2,
and 1543–1547, 1567–1574, 1595–1604, and 1630–1633 of domain
11 were defined as flexible. During the rigid-body energy minimization,
2,000 structures were calculated. For each of the 2,000 combinations,
5 rigid-body docking trials were performed, and only the solution with
the lowest energy was kept, amounting to a total of 10,000 rigid-body
minimization trials. The 200 best solutions based on the intermolecular
energy were used for the semiflexible simulated annealing, followed by
a refinement in explicit water. Finally, the solutions were clustered by
using a 2.5 A˚ rmsd based on the pairwise backbone rmsd matrix after
superposition on the backbone of domain 11.
Supplemental Data
Supplemental Data include the clustering of the IGF2:IGF2R domain
11 complex generated with all existing IGF2 mutagenesis data and
the statistical analysis of all of the HADDOCK docking runs on the
IGF2:IGF2R domain 11 complex and are available at http://www.
structure.org/cgi/content/full/15/9/1065/DC1/.
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